Data / Drug companies / International Medication Systems, Limited
International Medication Systems, Limited: 24 products in the FDA NDC directory, labeler code 76329
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
International Medication Systems, Limited (labeler code 76329) lists 24 products in the FDA National Drug Code Directory, covering 13 finished drugs by generic name. By type: 24 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on September 12, 2025.
The request: Watch International Medication Systems, Limited (FDA labeler code 76329): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 76329
- Products in commercial distribution
- 24
- Packages
- 25
- Finished drugs by generic name
- 13
- Prescription products
- 24
- Over the counter products
- 0
- Controlled substance products
- Schedule II 1, Schedule IV 1
- Flagged as original packager
- 23 of 23 products that carry the flag
- Started marketing in the last 12 months
- 0
- Products with a marketing end date set
- 1
- Earliest marketing start
- August 7, 1979
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 22 | 91.7% |
| New drug applications (NDA) | 2 | 8.3% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 24 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Lidocaine hydrochloride | 6 | 134 |
| Naloxone hydrochloride | 4 | 40 |
| Iron sucrose | 3 | 5 |
| Epinephrine | 2 | 32 |
| Calcium chloride | 1 | 14 |
| Dextrose monohydrate | 1 | 12 |
| Atropine sulfate | 1 | 24 |
| Morphine sulfate | 1 | 31 |
| Lorazepam | 1 | 38 |
| Sodium bicarbonate | 1 | 51 |
| Phytonadione | 1 | 31 |
| Regadenoson | 1 | 14 |
| Procainamide hydrochloride | 1 | 10 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection | 15 | 62.5% |
| Jelly | 4 | 16.7% |
| Injection, solution | 2 | 8.3% |
| Spray | 1 | 4.2% |
| Solution | 1 | 4.2% |
| Injection, emulsion | 1 | 4.2% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Iron Sucrose | 76329-9202 | Injection | Generic drugs (ANDA) | September 12, 2025 |
| Iron Sucrose | 76329-9201 | Injection | Generic drugs (ANDA) | August 12, 2025 |
| Iron Sucrose | 76329-9200 | Injection | Generic drugs (ANDA) | August 12, 2025 |
| Rextovy | 76329-3669 | Spray | New drug applications (NDA) | May 7, 2024 |
| Regadenoson | 76329-3321 | Injection, solution | Generic drugs (ANDA) | April 20, 2023 |
| Epinephrine | 76329-3318 | Injection | New drug applications (NDA) | January 30, 2023 |
| Morphine Sulfate | 76329-1912 | Injection | Generic drugs (ANDA) | January 20, 2022 |
| Dextrose Monohydrate | 76329-3302 | Injection, solution | Generic drugs (ANDA) | November 11, 2021 |
| Atropine Sulfate | 76329-3340 | Injection | Generic drugs (ANDA) | February 17, 2021 |
| Epinephrine | 76329-9060 | Injection | Generic drugs (ANDA) | May 19, 2020 |
| Calcium Chloride | 76329-3304 | Injection | Generic drugs (ANDA) | July 8, 2018 |
| Procainamide Hydrochloride | 76329-3399 | Injection | Generic drugs (ANDA) | December 21, 2016 |
| Naloxone Hydrochloride | 76329-3469 | Injection | Generic drugs (ANDA) | July 28, 2016 |
| Lorazepam | 76329-8261 | Injection | Generic drugs (ANDA) | December 1, 2012 |
| Lidocaine Hydrochloride | 76329-6300 | Solution | Generic drugs (ANDA) | June 19, 2012 |
| Phytonadione | 76329-1240 | Injection, emulsion | Generic drugs (ANDA) | April 18, 2003 |
| Lidocaine Hydrochloride | 76329-3390 | Injection | Generic drugs (ANDA) | June 1, 2001 |
| Naloxone Hydrochloride | 76329-3369 | Injection | Generic drugs (ANDA) | June 1, 2001 |
| Sodium Bicarbonate | 76329-3352 | Injection | Generic drugs (ANDA) | June 1, 2000 |
| Naloxone Hydrochloride | 76329-1469 | Injection | Generic drugs (ANDA) | April 1, 1988 |
| Lidocaine Hydrochloride | 76329-3015 | Jelly | Generic drugs (ANDA) | August 7, 1979 |
| Lidocaine Hydrochloride | 76329-3013 | Jelly | Generic drugs (ANDA) | August 7, 1979 |
| Lidocaine Hydrochloride | 76329-3012 | Jelly | Generic drugs (ANDA) | August 7, 1979 |
| Lidocaine Hydrochloride | 76329-3011 | Jelly | Generic drugs (ANDA) | August 7, 1979 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.